NSJ Bioreagents

SKU(재고 관리 코드):V6048-100UG

TNFSF15 Antibody / Tumor necrosis factor ligand superfamily member 15, 100ug

TNFSF15 Antibody / Tumor necrosis factor ligand superfamily member 15, 100ug

가격·납기 및 기술자료를 확인해 드립니다.

제품 규격과 수량을 선택한 후 견적을 요청해 주세요. 대체품 검토와 SDS·COA·데이터시트 요청도 함께 접수할 수 있습니다.

이 제품 견적 요청

대표번호 070-8028-3500 · info@rndmate.com

MULTI-BRAND QUOTE
여러 제품을 함께 찾고 계신가요?
제조사가 달라도 괜찮습니다. 필요한 연구시약을 한 번에 견적받아보세요.
통합 견적 요청
Size

DR3 Ligand antibody recognizes Tumor necrosis factor ligand superfamily member 15, also known as TNFSF15, VEGI, and TL1A, a cytokine that functions as the cognate ligand for Death Receptor 3, encoded by the TNFRSF25 gene. As the TNFRSF25 ligand, this protein plays a central role in immune regulation and inflammatory signaling. DR3 Ligand Antibody is developed to detect endogenous TNFSF15 in research applications focused on receptor-ligand biology and T cell activation pathways.<br><br>TNFRSF25, commonly referred to as DR3, is a member of the tumor necrosis factor receptor superfamily expressed on T lymphocytes and other immune cell populations. Binding of its ligand triggers downstream signaling cascades involving NF-kappaB activation and apoptosis-related pathways. Through this interaction, the TNFRSF25 ligand regulates T helper cell expansion, cytokine production, and adaptive immune responses. Dysregulated signaling in this pathway has been implicated in autoimmune disease, chronic inflammation, and immune-mediated tissue injury.<br><br>The gene encoding DR3 Ligand, TNFSF15, is located on chromosome 9q32 and produces a type II transmembrane protein that can be proteolytically cleaved to generate a soluble cytokine form. Expression has been documented in endothelial cells, antigen-presenting cells, and inflamed tissues. In addition to immune activation, the protein historically described as Vascular endothelial growth inhibitor exhibits anti-angiogenic properties, linking receptor-mediated immune signaling with vascular remodeling processes.<br><br>Altered TNFSF15 expression has been associated with inflammatory bowel disease, rheumatoid arthritis, and tumor-associated immune modulation. In oncologic contexts, VEGI has been investigated for its ability to influence tumor angiogenesis and immune microenvironment dynamics. These dual immune and vascular functions make DR3 Ligand a critical mediator at the interface of inflammation and endothelial biology.<br><br>Clone VEGI/13117 is a monoclonal antibody that recognizes the TNFRSF25 ligand and supports studies of DR3-mediated signaling, cytokine regulation, and immune pathway modulation in diverse experimental systems.<br><br>For additional TL1A / TNFSF15 / VEGI research antibodies targeting inflammatory cytokine signaling and TNF superfamily immune pathways, explore the broader <a href=../tds/recombinant-tl1a-antibody-tnfsf15-vegi-rvegi1283-v3637>TL1A Antibody</a> page featuring recombinant rabbit monoclonal clone rVEGI/1283.

Specifications

Catalog No V6048-100UG
Family Primary antibody
Qty 100ug
Formulation 0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide
Format Purified
Clone VEGI/13117
Host Animal Mouse
Clonality Monoclonal (mouse origin)
Isotype Mouse IgG2b, kappa
Species Reactivity Human
Application IHC
Application Details Immunohistochemistry (FFPE): 1-2ug/ml
Application Note Optimal dilution of the DR3 Ligand/TNFRSF25 Ligand antibody should be determined by the researcher.
Status Available
PDF Link Product Data Sheet (PDF)
Limitation This DR3 Ligand/TNFRSF25 Ligand antibody is available for research use only.
Uniprot # O95150
Immunogen A recombinant fragment (around amino acids 100-251) of human VEGI protein (exact sequence is proprietary) was used as the immunogen for the DR3 Ligand/TNFRSF25 Ligand antibody.
Storage DR3 Ligand/TNFRSF25 Ligand antibody with sodium azide - store at 2 to 8oC; antibody without sodium azide - store at -20 to -80oC.
Localization Membrane, Secreted
Title TNFSF15 Antibody / Tumor necrosis factor ligand superfamily member 15
전체 세부 정보 보기